Solid forms of a compound

Inventors

HALE, Christopher R.H. • Ran, Yingqing • Sudhakar, Anantha

Assignees

Denali Therapeutics Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12662458-B2

Patent

Publication Date

2026-06-23

Expiration Date


Abstract

Forms of 2-(4-chlorophenoxy)-N-[3-[5-[cis-3-(trifluoromethoxy)cyclobutyl]-1,3,4-oxadiazol-2-yl]-1-bicyclo[1.1.1]pentanyl]acetamide, designated herein as Compound I, were prepared and characterized in the solid state. Also provided are processes of manufacture and methods of using the forms of Compound I.

Core Innovation

The disclosure relates to solid forms of Compound I, 2-(4-chlorophenoxy)-N-[3-[5-[cis-3-(trifluoromethoxy)cyclobutyl]-1,3,4-oxadiazol-2-yl]-1-bicyclo[1.1.1]pent-1-yl]acetamide, an EIF2B modulator, comprising micronized Form A and Form C. Form A exhibits CuKα X-ray powder diffraction peaks at 22.2, 22.6, and 22.9 °2θ, while Form C exhibits peaks at 18.5, 23.3, 25.1, and 25.8 °2θ. The disclosure further encompasses pharmaceutical compositions and therapeutic uses of these polymorph forms for eukaryotic initiation factor 2B-mediated conditions.

Form C is characterized as a stable anhydrate associated with Form A; [procedural detail omitted for safety]. Form C possesses a higher melting transition and lower solubility than Form A, yet demonstrates comparable systemic exposure in animal pharmacokinetic studies. Characterization includes thermal, vapor-sorption, diffraction, and crystallographic analysis. The specific technical problem being solved is not explicitly described in patent.

Claims Coverage

The claims recite two independent claims directed to Form C and micronized Form A polymorphs, respectively, along with four primary inventive features.

Form C polymorph

A Form C polymorph of 2-(4-chlorophenoxy)-N-[3-[5-[cis-3-(trifluoromethoxy)cyclobutyl]-1,3,4-oxadiazol-2-yl]-1-bicyclo[1.1.1]pent-1-yl]acetamide, exhibiting an X-ray powder diffraction pattern using CuKα radiation with peaks at 18.5, 23.3, 25.1, and 25.8 degrees 2-theta.

Micronized Form A polymorph

A micronized Form A polymorph of the specified acetamide, exhibiting an X-ray powder diffraction pattern using CuKα radiation with peaks at 22.2, 22.6, and 22.9 degrees 2-theta.

Pharmaceutical composition

A pharmaceutical composition comprising the specified acetamide, wherein dependent claims specify at least 95% of the acetamide in crystalline form.

Treatment of EIF2B-mediated conditions

Methods and uses comprising administering an effective amount of Form C or Form A to treat a condition mediated at least in part by eukaryotic initiation factor 2B, including Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, and dementia.

In summary, the claims cover two diffraction-characterized solid forms of the acetamide compound, associated pharmaceutical compositions, and methods of treatment for EIF2B-mediated diseases.

Stated Advantages

Not explicitly described in patent.

Documented Applications

Pharmaceutical compositions containing Form A or Form C polymorphs.

Therapeutic use for diseases or conditions mediated at least in part by eukaryotic initiation factor 2B, including Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, and dementia.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.